Amgen Inc. (AMGN)
US FDA warns of liver injury cases tied to Amgen's rare disease drug
The U.S. Food and Drug Administration on Monday said it had identified cases of liver injury in patients taking Amgen's drug for a group of rare autoimmune diseases and urged healthcare providers to closely monitor patients and discontinue the treatment promptly if liver damage is suspected.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
In the most recent trading session, Amgen (AMGN) closed at $353.93, indicating a +1.58% shift from the previous trading day.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?
Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Amgen (AMGN) closed at $361.13 in the latest trading session, marking a -1.4% move from the prior day.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Bank of Nova Scotia Purchases 60,794 Shares of Amgen Inc. $AMGN
Bank of Nova Scotia raised its position in Amgen Inc. (NASDAQ: AMGN) by 56.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 167,609 shares of the medical research company's stock after acquiring an additional 60,794 shares during the
Amgen Inc. $AMGN Stock Position Decreased by Ameriprise Financial Inc.
Ameriprise Financial Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 18.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,000,946 shares of the medical research company's stock after selling 467,013 shares during the quarter. Ameriprise
Amgen: MariTide And Osteoporosis Sales Fuel The Rally
Despite the war in the Middle East, Amgen is trading near its 52-week high. One of the reasons is the strong growth in sales of its flagships in the oncology and cardiovascular franchises. So, Imdelltra, a drug used to treat extensive-stage small cell lung cancer, generated $234 million in net revenues for Amgen, up 249.3% year-over-year.
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc.
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
Novo Nordisk is a top player in the weight loss market and has several more products on the way. Amgen's most advanced candidate in this space could earn approval in the coming years.
